| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 7936 | 2011 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3054 | 2013 |
| Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study JM Sun, L Shen, MA Shah, P Enzinger, A Adenis, T Doi, T Kojima, ... The Lancet 398 (10302), 759-771, 2021 | 819 | 2021 |
| Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020 | 713 | 2020 |
| Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma Y Doki, JA Ajani, K Kato, J Xu, L Wyrwicz, S Motoyama, T Ogata, ... New England Journal of Medicine 386 (5), 449-462, 2022 | 549 | 2022 |
| Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial S Gourgou-Bourgade, C Bascoul-Mollevi, F Desseigne, M Ychou, ... J Clin Oncol 31 (1), 23-29, 2013 | 529 | 2013 |
| Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy P Rougier, R Bugat, JY Douillard, S Culine, E Suc, P Brunet, Y Becouarn, ... Journal of Clinical Oncology 15 (1), 251-260, 1997 | 527 | 1997 |
| Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases … C Cellier, T Sahmoud, E Froguel, A Adenis, J Belaiche, JF Bretagne, ... Gut 35 (2), 231-235, 1994 | 509 | 1994 |
| Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of … JY Blay, A Le Cesne, I Ray-Coquard, B Bui, F Duffaud, C Delbaldo, ... Journal of clinical oncology 25 (9), 1107-1113, 2007 | 503 | 2007 |
| Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial T Conroy, MP Galais, JL Raoul, O Bouché, S Gourgou-Bourgade, ... The lancet oncology 15 (3), 305-314, 2014 | 415 | 2014 |
| Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial D Peiffert, L Tournier-Rangeard, JP Gérard, C Lemanski, E François, ... J Clin Oncol 30 (16), 1941-8, 2012 | 370 | 2012 |
| Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial A Le Cesne, I Ray-Coquard, BN Bui, A Adenis, M Rios, F Bertucci, ... The lancet oncology 11 (10), 942-949, 2010 | 348 | 2010 |
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a … J Tabernero, HJ Lenz, S Siena, A Sobrero, A Falcone, M Ychou, ... The Lancet Oncology 16 (8), 937-948, 2015 | 337 | 2015 |
| Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and … B Melichar, A Adenis, AC Lockhart, J Bennouna, EC Dees, O Kayaleh, ... The Lancet Oncology 16 (4), 395-405, 2015 | 276 | 2015 |
| Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic … S Giacchetti, G Bjarnason, C Garufi, D Genet, S Iacobelli, M Tampellini, ... Journal of clinical oncology 24 (22), 3562-3569, 2006 | 228 | 2006 |
| Outcome of patients with platelet-derived growth factor receptor alpha–mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era PA Cassier, E Fumagalli, P Rutkowski, P Schöffski, M Van Glabbeke, ... Clinical Cancer Research 18 (16), 4458-4464, 2012 | 225 | 2012 |
| Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer M Ducreux, J Bennouna, M Hebbar, M Ychou, G Lledo, T Conroy, ... International journal of cancer 128 (3), 682-690, 2011 | 225 | 2011 |
| Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. T Kojima, K Muro, E Francois, CH Hsu, T Moriwaki, SB Kim, SH Lee, ... Journal of Clinical Oncology 37 (4_suppl), 2-2, 2019 | 206 | 2019 |
| Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors M Marty, P Fumoleau, A Adenis, Y Rousseau, Y Merrouche, G Robinet, ... Annals of Oncology 12 (11), 1643-1649, 2001 | 199 | 2001 |
| Quantifying circulating cell-free DNA in humans R Meddeb, ZAA Dache, S Thezenas, A Otandault, R Tanos, B Pastor, ... Scientific reports 9 (1), 5220, 2019 | 181 | 2019 |
